Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyMon, 10 Jun 2024 01:47:39 +0200Fri, 31 May 2024 12:00:00 +0200Summary of opinion: Tevimbra, 30/05/2024 Positivehttps://www.ema.europa.eu/en/medicines/human/variation/tevimbraSummary of opinion: Tevimbra, 30/05/2024 Positivehttps://www.ema.europa.eu/en/medicines/human/variation/tevimbraFri, 31 May 2024 12:00:00 +0200Human medicineTevimbra : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5919_en_3.pdfTevimbra : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5919_en_3.pdfWed, 22 May 2024 16:16:00 +0200Human medicineHuman medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 4, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/tevimbraHuman medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 4, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/tevimbraWed, 22 May 2024 11:58:00 +0200Human medicine